CommercialCoverageMedium impact
08.01.38e, Ocrelizumab (Ocrevus®) and Ocrelizumab and Hyaluronidase-ocsq (Ocrevus Zunovo™)
Independence Blue Cross·Neurology, Oncology·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
This is a new or updated pharmacy policy for Ocrelizumab (Ocrevus) and Ocrelizumab with Hyaluronidase-ocsq (Ocrevus Zunovo), used primarily for multiple sclerosis treatment. The policy became effective October 1, 2025 and may affect coverage, prior authorization requirements, or administration billing for these specialty medications.
Action Required
By October 1, 2025: Billing team should review the full policy details at the provided URL to understand specific changes to Ocrelizumab (Ocrevus) and Ocrelizumab with Hyaluronidase-ocsq (Ocrevus Zunovo) coverage requirements. Update prior authorization protocols and billing procedures for these medications as specified in the complete policy document.